William Guyer, Chief Development Officer, on June 02, 2026, sold 20,000 shares in Corcept Therapeutics (CORT) for $1,412,000. Following the Form 4 filing with the SEC, Guyer has control over a total of 3,985 common shares of the company, with 3,985 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1088856/000119312526257618/xslF345X05/ownership.xml
Douglas M. Schafer Jr, Executive Vice President and Chief Information Officer, on June 02, 2026, sold 48,000 shares in Miami International Holdings (MIAX) for $2,056,320. Following the Form 4 filing with the SEC, Schafer has control over a total of 396,681 common shares of the company, with 396,681 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1438472/000207944526000009/xslF345X05/wk-form4_1780605637.xml
Manmeet Singh Soni, Director, COO and CFO, on June 04, 2026, executed a purchase for 50,000 shares in Summit Therapeutics (SMMT) for $722,250. Following the Form 4 filing with the SEC, Soni has control over a total of 3,123,603 common shares of the company, with 3,123,603 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1599298/000156976926000004/xslF345X05/wk-form4_1780605646.xml
Edward Deitzel, Executive Vice President, Chief Regulatory Officer and Chief Compliance Officer, MIAX Exchanges, on June 02, 2026, sold 11,000 shares in Miami International Holdings (MIAX) for $463,760. Following the Form 4 filing with the SEC, Deitzel has control over a total of 116,221 common shares of the company, with 116,221 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1438472/000208067126000008/xslF345X05/wk-form4_1780605876.xml